Table 2 Biomarker levels in the HER2-positive breast cancer patients who showed normal (N) or reduced (R) left ventricular ejection fraction
Biomarkers | Group N (n = 10) | Group R (n = 9) | p-value |
|---|---|---|---|
hs-TnT (pg/mL) | |||
Baseline | 3.0 | 3.0 | |
3 months | 7.0 ± 5.8** | 9.2 ± 6.6* | 0.524 |
6 months | 4.0 ± 1.4 | 11.0 ± 7.8** | 0.005 |
9 months | 4.4 ± 2.7 | 3.6 ± 1.7 | 0.457 |
12 months | 3.9 ± 1.6 | 4.9 ± 2.1 | 0.321 |
15 months | 3.8 ± 1.0 | 4.4 ± 2.1 | 0.588 |
hs-TnI (pg/mL) | |||
Baseline | 4.2 ± 4.0 | 2.8 ± 2.9 | 0.426 |
3 months | 14.1 ± 7.0*** | 19.7 ± 17.3*** | 0.649 |
6 months | 10.6 ± 6.7** | 21.6 ± 16.4*** | 0.246 |
9 months | 7.3 ± 4.8 | 7.3 ± 6.1 | 0.621 |
12 months | 7.8 ± 5.9 | 8.7 ± 5.0 ** | 0.634 |
15 months | 10.3 ± 3.5** | 10.9 ± 6.4*** | 0.788 |
hs-CRP (mg/dL) | |||
Baseline | 0.04 ± 0.02 | 0.14 ± 0.18 | 0.112 |
3 months | 0.35 ± 0.27* | 0.71 ± 0.64* | 0.283 |
6 months | 0.09 ± 0.09 | 0.11 ± 0.12 | 0.393 |
9 months | 0.04 ± 0.03 | 0.05 ± 0.03 | 0.521 |
12 months | 0.18 ± 0.42 | 0.08 ± 0.11 | 0.867 |
15 months | 0.07 ± 0.07 | 0.85 ± 1.43 | 0.219 |
NT-proBNP (pg/mL) | |||
Baseline | 66.0 ± 30.5 | 46.6 ± 43.5 | 0.071 |
3 months | 56.4 ± 41.9 | 99.4 ± 76.9 | 0.337 |
6 months | 45.3 ± 32.8 | 22.9 ± 13.5 | 0.112 |
9 months | 39.5 ± 27.4 | 59.1 ± 27.2 | 0.093 |
12 months | 59.9 ± 51.4 | 52.1 ± 28.0 | 0.886 |
15 months | 61.1 ± 44.0 | 52.9 ± 26.4 | 0.795 |